Abstract 6P
Background
Agents targeting HER2 arepromising and the best studied therapies in patients with HER2-positive salivary duct carcinoma (SDC). RC48-ADC (Disitamab vedotin) is a novel humanized anti-HER2 antibody-drug conjugate (ADC). But the efficacy and safety of RC48-ADC is still unknown in metastatic SDC with HER2-positive.
Methods
Eligible patients from Zhejiang Cancer Hospital were 35∼76 years old, with confirmed, histologically HER2 expression (IHC1+, 2+, 3+), metastatic SDC. Patients had at least one line of systemic chemotherapy. Patients received RC48-ADC at 1.5 or 2 mg/kg, every two weeks. Clinical efficacy and safety were assessed.
Results
This study enrolled HER2-expressing metastatic SDC patients from June 2022 to Dec 2022. 10 mSDC patients (8 males, 2 females) were enrolled. 90% patients had received ≥2 lines systemic chemotherapy. 80% patients had visceral metastases. As of 05 Jan 2023 (data cutoff), 1 patient achieved CR, 4 patients achieved PR, 4 patients achieved SD, and only 1 patient achieved PD. The overall confirmed DCR was 90%. Most common treatment-related AEs were hypoaesthesia (70%), asthenia (60%), leukopenia (30%), decreased appetite (20%), alopecia (10%). The grade≥3 TRAEs only included hypoaesthesia (30.0%) and neutropenia (10%).
Conclusions
RC48-ADC showed a promising efficacy with a manageable safety profile in HER2-expressing mSDC patients who had failed at least one line of systemic chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - Bcl-xL prevents the arginine starvation induced by PEGylated arginine deiminase (ADI-PEG20) from inducing apoptosis
Presenter: Brian Van Tine
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges
Presenter: Nadezhda Knauer
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Quantitative indicators of TREC and KREC excision rings in malignant neoplasms
Presenter: Alexander Sultanbaev
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Presenter: Gulsah Nomak
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model
Presenter: Samart Phuwapraisirisan
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Co-expression analysis of genes encoding proteasome subunits and XPO1-related proteins in the Cancer Genome Atlas (TCGA) and the Gene Tissue Expression (GTEx) databases as a tool to devise new treatment strategies
Presenter: Vito Spataro
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer
Presenter: Ryuk Jun Kwon
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma
Presenter: Masato Inazu
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Knockout of lncRNA-CCAT1 with the use of CRISPR-Cas9 system and G7 PAMAM dendrimers influences apoptosis and proliferations of NSCLC cells
Presenter: Mateusz Iwanski
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Censoring imbalance in ACIS trial for prostate cancer
Presenter: Noa Zimhony-Nissim
Session: Cocktail & Poster Display session
Resources:
Abstract